Care Giant Posts $5.1 Billion Revenue, Investor Grows Stake
A premier eye care company delivers $5.1 billion in revenue, while a prominent investor quietly expands holdings. Her...
Healthcare Stocks
This tag page curates 5 Healthcare Stocks articles to help you assess risks, dividend potential, and notable moves from Chemed to UnitedHealth, helping smarter investment decisions.
85 articlesBarclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Lantheus Holdings Stock Popped Last Month: Key Drivers
An almost 12% jump in lantheus holdings stock popped last month left investors asking what lit the fuse. This article...
Novo Nordisk Slashing Prices Could Boost the Stock
Novo Nordisk slashing prices is drawing attention from investors who wonder how a price cut could actually lift the s...
Oscar Health’s Says 2026 Profit Turnaround Gains Steam
Oscar Health is betting on a 2026 profitability turnaround after a challenging Q4 2025, highlighting AI efficiency, h...
Ardent Health (ARDT) 2025 Q4 Earnings Outlook for Investors
As Ardent Health closes 2025, the Q4 results shed light on margins, volumes, and balance-sheet health. This analysis ...
Viemed (VMD) 2025 Earnings Outlook for Investors Today
Viemed's 2025 earnings outlook hinges on growing demand for home respiratory care, reimbursement dynamics, and cost c...
Hims Hers: Telehealth Growth and Investor Tactics for Beginners
Telehealth is changing how we get care—and how we invest. This article breaks down the growth story, uses Hims & Hers...
Orthofix (OFIX) 2025 Earnings Outlook and Key Drivers
As orthofix prepares its 2025 earnings narrative, investors weigh product mix shifts, margins, and macro headwinds. T...
Option Care (OPCH) Earnings: A Deep-Dive for Investors
Option Care earnings season sheds light on the shifting landscape of home infusion and specialty care. This guide bre...
Hims Hers Stumbles Open as Regulatory Damage Hits Outlook
Hims & Hers Health fell after guiding Q1 2026 revenue below expectations, citing a $65 million headwind from regulato...
Biotech Fund Doubles Down: Scholar Rock Bet Drives 26% Rally
A major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...